Futures surge after Moderna (MRNA) says Phase 3 study met statistical criteria with a vaccine efficacy of 94.5%
Tweet Send to a Friend
Futures surge after Moderna ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
